{"name":"NRG Oncology","slug":"nrg-oncology","ticker":"","exchange":"","domain":"nrgoncology.org","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Gonadotrophin Releasing Hormone","genericName":"Gonadotrophin Releasing Hormone","slug":"gonadotrophin-releasing-hormone","indication":"Hormone-sensitive prostate cancer","status":"phase_3"},{"name":"Adjuvant Chemotherapy + Ovarian Function Suppression","genericName":"Adjuvant Chemotherapy + Ovarian Function Suppression","slug":"adjuvant-chemotherapy-ovarian-function-suppression","indication":"Premenopausal women with early-stage breast cancer (adjuvant setting)","status":"phase_3"},{"name":"CAPOX 3 month","genericName":"CAPOX 3 month","slug":"capox-3-month","indication":"Colorectal cancer","status":"phase_2"},{"name":"CAPOX 6 month","genericName":"CAPOX 6 month","slug":"capox-6-month","indication":"Colorectal cancer","status":"phase_2"},{"name":"Ovarian Function Suppression + Aromatase Inhibitor","genericName":"Ovarian Function Suppression + Aromatase Inhibitor","slug":"ovarian-function-suppression-aromatase-inhibitor","indication":"Hormone receptor-positive, HER2-negative breast cancer in premenopausal women (adjuvant or metastatic setting)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Imaging Agent","genericName":"Imaging Agent","slug":"imaging-agent","indication":"Other","status":"phase_2"},{"name":"mFOLFOX6 6 month","genericName":"mFOLFOX6 6 month","slug":"mfolfox6-6-month","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Gonadotrophin Releasing Hormone","genericName":"Gonadotrophin Releasing Hormone","slug":"gonadotrophin-releasing-hormone","phase":"phase_3","mechanism":"Gonadotropin-releasing hormone (GnRH) agonists stimulate the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, which initially increases sex hormone production before causing downregulation and suppression of testosterone and estrogen.","indications":["Hormone-sensitive prostate cancer","Hormone-sensitive breast cancer"],"catalyst":""},{"name":"Adjuvant Chemotherapy + Ovarian Function Suppression","genericName":"Adjuvant Chemotherapy + Ovarian Function Suppression","slug":"adjuvant-chemotherapy-ovarian-function-suppression","phase":"phase_3","mechanism":"This combination treatment uses chemotherapy drugs to kill cancer cells while simultaneously suppressing ovarian function to reduce estrogen production and protect fertility in premenopausal women with breast cancer.","indications":["Premenopausal women with early-stage breast cancer (adjuvant setting)","Hormone receptor-positive breast cancer with ovarian function preservation"],"catalyst":""},{"name":"CAPOX 3 month","genericName":"CAPOX 3 month","slug":"capox-3-month","phase":"phase_2","mechanism":"Capecitabine is a thymidylate synthase inhibitor.","indications":["Colorectal cancer","Breast cancer","Stomach cancer"],"catalyst":""},{"name":"CAPOX 6 month","genericName":"CAPOX 6 month","slug":"capox-6-month","phase":"phase_2","mechanism":"Capecitabine is a thymidylate synthase inhibitor.","indications":["Colorectal cancer","Breast cancer","Stomach cancer"],"catalyst":""},{"name":"Imaging Agent","genericName":"Imaging Agent","slug":"imaging-agent","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ovarian Function Suppression + Aromatase Inhibitor","genericName":"Ovarian Function Suppression + Aromatase Inhibitor","slug":"ovarian-function-suppression-aromatase-inhibitor","phase":"phase_3","mechanism":"This combination suppresses ovarian estrogen production while blocking the conversion of androgens to estrogen, reducing total circulating estrogen in premenopausal women with hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive, HER2-negative breast cancer in premenopausal women (adjuvant or metastatic setting)"],"catalyst":""},{"name":"mFOLFOX6 6 month","genericName":"mFOLFOX6 6 month","slug":"mfolfox6-6-month","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPVEZyMWl3elNqZl9kSFp4UDZyNjMxT2RkWmZQRl9OOWh2eFlLQ0hBRVNkSnB0MVlnckxtQ1RJb1FiRW1PdjV3S1lHNWlsUjVmNXpJa3UwU0U1UjhGcHVKYjV2eVllRzExT3RqTGJMX3oyZmVYWWhsZXFzbnpUV0piMVdrU1BqVV9WdGVzWVNMN0cwOHU3T1pRRHloQUpXSUJBT3I0Q3FZVFVoX2ZFVnVJNmhXVlo2alV2S1NBSTE3dEJGV3c?oc=5","date":"2025-10-25","type":"pipeline","source":"The ASCO Post","summary":"Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer - The ASCO Post","headline":"Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPWlVaMUVmelpTQ2I2LUY1Rk95QVBWSUV2Tlh3eHBzTHpoOUM0MW5DUVNPZFlsVTk3TDBDY2RocU40RDdvbmp5Yks2Q2RaOEx1MEhvNUxLM2h3WnptMVhCdUpkWVFJa0x6eUlxNGNuZUVWSTdfbjc0SFRCZXhLZ1FVYVlxTDdxSUx4SFlXQXp4QUZOcGJoVEtfZTdOaGNwQ1FOZ2NZSDk0NzZmTzFvTEtqdA?oc=5","date":"2025-08-07","type":"regulatory","source":"The Pharmaceutical Journal","summary":"Immunotherapy plus chemotherapy approved for endometrial cancer - The Pharmaceutical Journal","headline":"Immunotherapy plus chemotherapy approved for endometrial cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOem02enlmSThWdVFyRmpnYWhrbEQtQ1VVTEZIU0haZTlzUmZsQldPMkZCRXVQYmxKT2RIZWpCdWdCYjdYUzhFZ0o0VTlWMGx3Vzh1eFBxemRXYXlLLUtLUXZQcGVtVjFvREJNd19VdTVJN0FNZzA0MWYzS1VNSkNHQ1o2VEVtZHJoanRaaUduWXdUR3VzSGRVUWxGUXV5bnR5Z044U3ptM2QwTDI3T2dQSFBkV0JOY2s?oc=5","date":"2025-04-23","type":"pipeline","source":"ASCO Daily News","summary":"Treatment for Pancreatic Cancer in Patients With Positive Lymph Nodes After Complete Resection: Is There a Role for Radiotherapy? - ASCO Daily News","headline":"Treatment for Pancreatic Cancer in Patients With Positive Lymph Nodes After Complete Resection: Is There a Role for Radi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9DeWdDdjFYQXR0WF9hWHB1b21mNk51NDFyc2dWVHJSelJsanlROVA2NGM5bUZFNnlsb01XeVhUOWFUa2IwUGl6S2JySWVvdEdxYU1HVHJTcUlfcVl3Vm1zTTE5UWpGckVyRnN2cg?oc=5","date":"2025-03-20","type":"trial","source":"Clinical Trials Arena","summary":"Flatiron and NRG Oncology to deploy EHR-to-EDC technology in multi-centre trial - Clinical Trials Arena","headline":"Flatiron and NRG Oncology to deploy EHR-to-EDC technology in multi-centre trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRTBrOHp1RUdhYWFONXVTN3RZNWpWb1JVSHV1SFByZjBXWEtReGE1TWFSREpuUl9zNzZWb0hwb3NBRW5kT1EzcmlVVU5vcVZ6NFpFX3dOOTBUdjk0ZmlCZnlCeW10TmxyZGZHN1R2cFZwRjF0SDZrTlRiVjFISEZ0SUJmRTBmb2w3ekRYX19GYWk2NExTVU0zam9nM1Z2N2lqUl9CS3prQXYxSG93aU9yWExsYmloSUF0dk53eUlVOEJMQ2s?oc=5","date":"2025-03-19","type":"trial","source":"Fierce Biotech","summary":"Flatiron Health irons out pact to bring data capture tech to National Cancer Institute trial sites - Fierce Biotech","headline":"Flatiron Health irons out pact to bring data capture tech to National Cancer Institute trial sites","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5sZnB5ZV9yRV91ekdqRmxSbllVcHBIU2VTemR4d09RNG1wdC1sZEJkRm9CVjJ3YXNYVGwyc0YzYnFtODJ3R0prRV9LbzVZUnp1NWZOb2lfU2dfdE5WVV9CSGJhM1Y1bV9RWWlmZFQwZzMyRXktbXExVHRiM0x0ajA?oc=5","date":"2025-01-15","type":"pipeline","source":"Cancer Therapy Advisor","summary":"SABCS 2024: Research Roundup - Cancer Therapy Advisor","headline":"SABCS 2024: Research Roundup","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1EMG16UmYtX2xkZHZ0SUJINXpEWTY2c09sMHRUYjdWUmd5a0R1N2Y3TlBDQ2RnM1llaDFxVllraWJOQlM0UTVUbW9DeVA3WDhNQUpZVHZiYkk4NGxtVkFF?oc=5","date":"2025-01-09","type":"trial","source":"nature.com","summary":"Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial - nature.com","headline":"Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOR1FpUHF1Z0wtZ083clhSQ1FzNm4zVjh0ZTFvWmVoRHdqX2xKeDBBZGkzY2VMNnpfTG05eWRnZXprY0pVRFdPb2hnb3lpWW9TTi1mUE9QMnFrb0h3QWdWdlZsS3Z4Z0V0X1RtY2hxUlF4dVZVV1FKenVSNGo1OUF2RnBpbk9NRVZTcnJnOGw4dlhqcHc2cWlKbE9vS1F5RmlkcWd5eV9GdmRQdjB4Ulg4LVQ0ZmFjSGNsSm91R3BtVC1qVGpFejZKRTJZVmdLX3Z1ZXRqMW5Pb1hkU2RlQTByX2JFTmpnU3g1VDZ6VTRiMTdURlQ1Y1VsMUtfZ2NJZGVNMzNoenBhVHZoMU9aUEdRbnJpOWc?oc=5","date":"2024-12-11","type":"trial","source":"AstraZeneca","summary":"Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial - AstraZeneca","headline":"Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOMURzZ2FBdHJudkdZWEpwQktYU0EyckNCOVN4VmgyRnNuZ0tuT2tnYmk3RDNKWmZxejhPeHhBbTZmTkNzalVXR1JodVlnSTJXVW5fTjA0VVR0eV82Q1o0TWRScnlHVENTYVZIY2ZmNWtZSjlBWlpNX0RxR1RmVGdoVlNyMmpSQW5NTWpF?oc=5","date":"2024-10-01","type":"trial","source":"The Lancet","summary":"Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the Americ","headline":"Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations fr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNeTVwVHR1T1Fjd1hVSzNiRU9TaXVlNl9RaWZPMW41Um1VQXFmWVV0ZXJhVTVZbGRidDRGdEVnRTU3ekZieEdlUC14cmk1aUQ1QmZ4YXo2QkVycWMwTkJhMHppQWhLNFNTb3d2cUpFOWp0a3h2d1VPZkxka0xTV052Tjd1UXFfRmcwTWNnX2xlYzB4V1R5SldrR1RiV1hQekt2WWEwSw?oc=5","date":"2023-06-01","type":"pipeline","source":"National Cancer Institute (.gov)","summary":"NCI’s ComboMATCH initiative will test new drug combinations guided by tumor biology - National Cancer Institute (.gov)","headline":"NCI’s ComboMATCH initiative will test new drug combinations guided by tumor biology - National Cancer Institute (.gov)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQZVZDOERyNnl5ZldKU1lhTXUzU1NpTVhTclUwMzFUTG5DTUZWVXJaenFSZm1taEoxVzh2SzB1WWF1dXlLZk9aa0hQbFg3dWJmYlJCTnNBaFBYTFNQNDBPQ1g0QmN1eVliNHZPLWs4UngxV1N5Y3JGMWMyUDNjYU9jRWIydlB2Zw?oc=5","date":"2023-02-06","type":"trial","source":"pharmaphorum","summary":"Keytruda shadows GSK's Jemperli in endometrial cancer - pharmaphorum","headline":"Keytruda shadows GSK's Jemperli in endometrial cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNU3RTNGNlX3NfLTdfRkxOM0tHWjAtQktsOTVrX3A1dUhhbU9OSmFMbWpLejdWbUszMjZhMXdvSUo2eGpvZEJGcHM4TFRDaHVsM3Fhdm5nd1duR3pueEJ0UDFZRUZvSk9rbS1nTTY5d3Uwb0JaWFB2ZzBKQzloZ2lGUFFvTlNNRzFI?oc=5","date":"2021-11-08","type":"pipeline","source":"Imaging Technology News","summary":"Radiation Oncology Research Featured at ASTRO 2021 - Imaging Technology News","headline":"Radiation Oncology Research Featured at ASTRO 2021","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":3,"phase_2":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}